

From: [Kris Lindsay](#)
To: [Claire Matheson](#); [Simon Mollart](#)
Subject: Re: NP30723 - Assurance of CO2 Supply Position
Date: 23 April 2026 08:57:55
Attachments: [image001.jpg](#)
[image002.png](#)

Thanks Claire, yes I'll feed this into our SITREP that we provide to SG

KR

Kris Lindsay

**Head of Strategic Sourcing & Commercial | National Procurement
Public Services Delivery Scotland**

Gyle Square | 1 South Gyle Crescent

Edinburgh | EH12 9EB

e: [REDACTED]@nhs.scot

t: [REDACTED]

[publicservicesdelivery.scot](#)

From: Claire Matheson [REDACTED]@nhs.scot>
Sent: Wednesday, April 22, 2026 17:04
To: Kris Lindsay [REDACTED]@nhs.scot>; Simon Mollart [REDACTED]@nhs.scot>
Subject: FW: NP30723 - Assurance of CO₂ Supply Position

Hi Both

Please see response from BOC. Are we coordinating a response to SG that this can feed into?

Thanks
Claire

From: [REDACTED]@nhs.scot>
Sent: 22 April 2026 11:53
To: Claire Matheson [REDACTED]@nhs.scot>
Subject: FW: NP30723 - Assurance of CO₂ Supply Position

Hi Claire, please see below assurance from BOC.

It is reassuring that supply remains uninterrupted at present, although a further price increase may be expected.

Kind Regards,

[REDACTED] | **Public Services Delivery Scotland**
Gyle Square | 1 South Gyle Crescent
Edinburgh | EH12 9EB
e: [REDACTED]@nhs.scot

From: [REDACTED]@boc.com>
Sent: 21 April 2026 17:26
To: [REDACTED]@nhs.scot>
Cc: [REDACTED]@boc.com>
Subject: RE: NP30723 - Assurance of CO₂ Supply Position

Hi [REDACTED]

Please find below our official response in relation to your query:

Customer Update: Supply Continuity and Product Availability

We would like to inform you that we are not currently experiencing any disruption to supply as a result of the ongoing geopolitical situation. We continue to monitor the evolving situation and will update you should this situation change.

We are also tracking movements in gas prices, as well as wider fuel and energy costs. Any pricing adjustments arising from these factors will be communicated where appropriate.

Below is an overview of our key medical gas products and how they are sourced:

Medical Oxygen: Medical Oxygen is our primary product for the healthcare sector and is manufactured in the UK across several BOC-owned Air Separation Units (ASUs). We therefore anticipate minimal to no impact on product availability. Please note that oxygen production through ASUs is an energy-intensive process; as such, pricing may be affected by fluctuations in energy costs.

Synthetic Medical Air: Produced through the same ASU network, we also expect no major disruption to the supply of Synthetic Medical Air, though again costs may be impacted.

Medical Carbon Dioxide (CO₂) & Carbogen: This is currently sourced from EU based supply points, as well as being produced internally by BOC. Due to the influence of the fertiliser market on CO₂ pricing, costs from EU sources may rise, but supply availability remains secure.

Nitrous Oxide (N₂O) and Entonox®: These products are currently sourced from Europe, with pricing similarly linked to the fertiliser market. We also maintain strategic stock levels within the UK, ensuring a robust and protected supply position.

Helium & Heliox: As communicated in our separate Helium statement, Linde PLC (our Parent Company) has needed to adjust its global distribution strategy in response to current market conditions. This has resulted in significant additional costs associated with transportation, storage, processing, and procurement to maintain reliable global supply. To ensure ongoing security of supply, recovery of these incremental costs has become necessary.

Please be assured that medical gas supplies will always remain our highest priority. In the event of any supply constraints, BOC Healthcare customers will be prioritised over other sectors we supply, ensuring continued support for patient care.

Kind Regards

[REDACTED]


BOC Healthcare

Forge, 43 Church Street West, Woking, Surrey, GU21 6HT, United Kingdom

Mobile: [REDACTED], [REDACTED] [@noc.com](mailto:[REDACTED]@noc.com), www.bocgases.co.uk



Find us on: [Facebook](#) | [Twitter](#) | [LinkedIn](#)



Sent from BOC Limited, registered in England & Wales, company number 337663. Registered office: Forge, 43 Church Street West, Woking, Surrey, GU21 6HT, England. BOC Limited is a subsidiary company of Linde plc. BOC Limited is authorised and regulated by the Financial Conduct Authority, reference number 715528. The BOC and Linde logos and the BOC and Linde words are trademarks or registered trademarks of Linde plc or its affiliates.

From: [REDACTED] [@nhs.scot](mailto:[REDACTED]@nhs.scot)>

Sent: 16 April 2026 15:44

To: [REDACTED] [@noc.com](mailto:[REDACTED]@noc.com)>; [REDACTED] [@noc.com](mailto:[REDACTED]@noc.com)>

Cc: Claire Matheson [REDACTED] [@nhs.scot](mailto:[REDACTED]@nhs.scot)>

Subject: NP30723 - Assurance of CO₂ Supply Position

Importance: High

CYBERSECURITY ALERT: This is an email from an external organization. Use caution, especially with links and attachments.

[More](#)

Good afternoon,

Hope you are both well.

It has come to our attention that, due to the ongoing conflicts in the Middle East, there may be risks of carbon dioxide supply disruption within the UK.

In light of this, would you be able to advise on your current supply position and provide assurance of the continued supply of CO₂ to NHS Scotland?

In addition, within BOC's tender submission, you noted that BOC produces its own carbon dioxide at a facility based at Trafford Park, and that additional testing was being undertaken prior to utilising this site for medical use. Could you please confirm whether this facility is now being used for the supply of medical-grade CO₂? It would be helpful to have assurance that carbon dioxide is also produced locally.

We would appreciate your response and any assurance you are able to provide on the above.

Kind Regards,

 | **Public Services Delivery Scotland**
Gyle Square | 1 South Gyle Crescent
Edinburgh | EH12 9EB
e: @nhs.scot
publicservicesdelivery.scot

This email is intended for the named recipient only. If you have received it by mistake, please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

The information contained in this email and any attachments may be confidential and is provided solely for the use of the intended recipient(s). If you are not the intended recipient, you are hereby notified that any disclosure, distribution, or use of this e-mail, its attachments or any information contained therein is unauthorized and prohibited. If you have received this in error, please contact the sender immediately and delete this e-mail and any attachments. No responsibility is accepted for any virus or defect that might arise from opening this e-mail or attachments, whether or not it has been checked by anti-virus software.

Please find the data protection notices of EU based Linde plc companies on this website: dataprotection.linde.com